Wiley InterScience :: Journal :: Article PDF

Wiley InterScience :: Journal :: Article PDF

Comments

Post a Comment

Popular posts from this blog

Intermittent androgen deprivation therapy...duration of tumor control.

Image
I frequently see patients with prostate cancer that want to know how long they will respond if they choose to be treated with intermittent androgen deprivation therapy (IADT). This involves the injection of a drug such as Lupron or Zoladex (LHRH agonist) usually on a 1-3 month basis plus or minus the ingestion of pills such as Celebrex, Flutamide, Nilutamide (anti-androgens) and Proscar or Avodart (inhibitors of activation of testosterone). A study by A. De La Taille et al. from France attempts to answer the question. From 1989 through 2001 these researchers studied 146 patients who had never receive hormone therapy before. They were treated in an intermittent fashion with LHRH agonist (Lupron, Zoladex) + non-steroidal anti-androgen (Flutamide, Casodex) = 28, LHRH alone = 42, non steroidal anti-androgen alone (i.e. Casodex, Flutamide) = 86. Disease Extent: Localized + locally advanced + metastatic prostate cancer = 72. Prostate-specific antigen (PSA) recurrence after radical pro...
Read more
Image
Multiple Myeloma Yields To Newer Therapy Many tears ago when I was teaching residents and fellows at Manhattan's Lennox Hill Hospital there wasn't much new to teach. We had old medications including Cytoxan and other cytoxan-like medications and prednisone or dexamethasone (decadron). If patients relapsed from this therapy they were offered an autologous bone marrow transplantation after receiving very high doses of similar medications or high-doses of the old therapies without transplant. It took several years to appreciate that the transplants actually extended the survival for many patients eligible to receive such therapy. Survivability from transplantation rapidly increased when done at the transplant centers. The procedure was initiated at M.D. Anderson hospital in Houston and subsequently fame came to the state of Arkansas which rapidly became the myeloma transplant center for the USA. Now, as indicated in the accompanying schema above we have several new and v...
Read more